Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin

@article{Liu2016EpigeneticAO,
  title={Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin},
  author={Yanqing Liu and Xiaoli Zheng and Qinqin Yu and Hua Wang and Fuqing Tan and Qianying Zhu and Lingmin Yuan and Huidi Jiang and Lushan Yu and Su Zeng},
  journal={Science Translational Medicine},
  year={2016},
  volume={8},
  pages={348ra97-348ra97}
}
Renal cell carcinoma (RCC) is known for its multidrug resistance. Using data obtained from the cancer transcriptome database Oncomine and the proteome database The Human Protein Atlas, we identified the repression of organic cation transporter OCT2 as a potential factor contributing to oxaliplatin resistance in RCC. By analyzing OCT2 expression in collected patient tissues and commercial tissue microarray specimens, we demonstrated OCT2 repression in RCC at both transcription and protein levels… CONTINUE READING
14
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-10 OF 14 CITATIONS

The Role of DNA Methylation in Renal Cell Carcinoma

  • Molecular Diagnosis & Therapy
  • 2018
VIEW 2 EXCERPTS
CITES BACKGROUND

Multiple drug transporters mediate the placental transport of sulpiride

  • Archives of Toxicology
  • 2017
VIEW 2 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 53 REFERENCES

The UCSF-FDA TransPortal: a public drug transporter database.

  • Clinical pharmacology and therapeutics
  • 2012
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Resistance to Targeted ABC Transporters in Cancer

  • Resistance to Targeted Anti-Cancer Therapeutics
  • 2015
VIEW 1 EXCERPT